28.02.2024 - Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End .
By Denny Jacob Codexis shares were up 19% at $2.48 a day after it entered into an agreement with Aldevron. The stock is down about 47% on the year so far..
/PRNewswire/ The industrial enzymes market size is forecasted to increase by USD 2.19 billion from 2022 to 2027, at a CAGR of 6.26%, according to the recent.